New Germline TP53 Variant in Breast Cancer Patient After Radiotherapy
Author Information
Author(s): Bruna Bianca Lopes, Silva Sávio Solon Alves, Dinoa Vanessa, Diniz Tadeu, Pereira Emilio, Bustamante Carolina, Garicochea Bernardo
Primary Institution: Oncoclinicas Group, Rio de Janeiro, Brazil
Hypothesis
Can radiotherapy in breast cancer patients lead to the discovery of new germline mutations associated with Li-Fraumeni syndrome?
Conclusion
The study identified a previously undescribed pathogenic variant in the TP53 gene in a breast cancer patient who developed angiosarcoma after radiotherapy.
Supporting Evidence
- The patient had a previous diagnosis of breast carcinoma treated with radiotherapy.
- A pathogenic variant in the TP53 gene was identified through genetic testing.
- The presence of angiosarcoma in a radiotherapy bed raises suspicion for Li-Fraumeni syndrome.
- Testing breast cancer patients under 65 can reveal new mutations.
Takeaway
This study shows that breast cancer patients who have had radiotherapy might have hidden genetic mutations that can lead to other cancers, like angiosarcoma.
Methodology
The case report involved genetic testing and clinical evaluation of a breast cancer patient who developed angiosarcoma after radiotherapy.
Limitations
The study is based on a single case report, limiting the generalizability of the findings.
Participant Demographics
The patient is a 47-year-old female with a history of bilateral breast cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website